Merck's Arcoxia Draws Mixed Reviews
13th Nov 2006, 16:01 GMT
The first published studies of Merck's Arcoxia, the drug it hopes will take the place of Vioxx, are getting mixed reviews from doctors.
Merck's Arcoxia Draws Mixed Reviews related news:
- Docs Give Merck Painkiller Acroxia Mixed Reviews — FOXNews.com
- Mixed reviews for Vioxx successor — MSNBC.com: Health
- Vioxx-Like Drug Gets Mixed Reviews — Dayton Daily News National Headlines
- Results on Merck's new painkiller draw mixed reviews — azcentral.com | business
- Tests of new Merck painkiller criticized — baltimoresun.com - health & science
- Results Mixed on Merck's New Painkiller — LancasterOnline - Health
- Results mixed on Merck's new painkiller (AP) — Yahoo! News: Health News
- Results mixed on Merck's new painkiller (Associated Press) — Yahoo! Health: Health News
- Merck: New pain killer safer than Vioxx — Business and financial news - CNNMoney.com
- Merck says new drug is safer than Vioxx — Cardiology News from StratCenter.com
Latest news from WSJ.com: US Business:
- Benetton Top Executives Resign
- Apple Names Rosenberg General Counsel
- Gutierrez Aims to Help U.S. Business in China
- Tyson Swings to Loss as Demand Wanes
- Eddie Bauer Agrees to Be Acquired
- Web Companies Seek Review of Fees
- Delta Cuts Bargain Fares
- Illumina to Buy Solexa for $600 Million
- BlackJack Is BlackBerry's Newest Rival
- Internet Firms Seek SEC Review